Lancell is in the process of developing a molecular treatment that activates dendritic cells when applied topically to the skin over a vaccine injection site. The vaccine, combined with the Lancell treatment, activates strong, rapid T cell immunity and may also induce strong, rapid antibody protection that accelerates the vaccine's effectiveness. This treatment can be used with any type of current vaccine, as well as those that are under development (the much anticipated avian flu vaccine, for example).
